The American Academy of Sleep Medicine (AASM) has released a new clinical practice guideline with updated recommendations for treating restless legs syndrome (RLS) in adults.

The International Neuromodulation Society (INS) recently welcomed Prof. Konstantin Slavin as its new President. A distinguished neurosurgeon with expertise in functional and stereotactic neurosurgery, Prof. Slavin brings over 30 years of experience, including notable contributions to chronic pain management, movement disorders, epilepsy, and psychiatric conditions. touchNEUROLOGY extends its best wishes for a successful presidency.

A new study published in Nature Neuroscience1 has uncovered significant insights into the progression of Alzheimer’s disease (AD), providing a new understanding of how the disease damages the brain. Funded by the National Institutes of Health (NIH) and led by researchers from the Allen Institute, this study used advanced brain mapping and genetic tools to explore the cellular-level changes that occur throughout AD. The findings reveal that Alzheimer's progresses in two distinct phases, offering potential avenues for early diagnosis and treatment strategies.

I’m an old clinician; I graduated in Medicine in 1963 at the University of Padova, Italy, and I’m proud to be on the editorial board of touchNEUROLOGY. With this in mind, I would like to express my opinions on ...

A study published in The Lancet Neurology reveals a troubling stagnation in the progress against stroke burden worldwide, with incidence rates failing to decline significantly since 2015. This analysis of the Global Burden of Disease (GBD) Study 2021 shows that the absolute numbers of strokes, related deaths and disability-adjusted life years (DALYs) have all risen considerably from 1990 to 2021, despite earlier global efforts aimed at reducing stroke mortality

Watch leading experts explain the shifting diagnostic paradigm in Alzheimer’s disease using case studies demonstrating the utility of biomarkers

In our latest Q&A, we are delighted to welcome Editorial Board member Dr David Hafler, William S. and Lois Stiles Edgerly Professor and Chairman of the Department of Neurology at Yale School of Medicine, as well as Neurologist-in-Chief at Yale-New Haven Hospital. Dr Hafler's groundbreaking work in multiple sclerosis (MS) research has helped establish the disease as an autoimmune disorder and led to the development of therapies such as natalizumab. His contributions include identifying myelin-reactive T cells, uncovering the genetic and molecular mechanisms underlying MS, and exploring the role of salt in driving autoimmune responses. A highly cited neurologist, he has received numerous awards, including the Dystel Prize, the Raymond Adams Award, and the NIH Javits Investigator Award, and is a member of the National Academy of Medicine.

In this next Q&A we welcome Prof. Dr Murat Emre. Prof. Emre studied medicine in Istanbul University and specialized in neurology in Zurich University Hospital in Zurich, Switzerland. After his training he did fellowships in movement disorders in Queen Square Hospital London and in behavioural neurology in Beth Israel Hospital, Harvard Medical School in Boston, he also worked in clinical research to develop new drugs for Parkinson's disease and Azlheimer disease. Upon his return to Turkey he founded the Movement Disorders and behavioural Neurology Unit in the Department of Neurology, İstanbul Faculty of Medicine. His main areas of interest are Parkinson!'s disease, in particular cognitive aspects/dementia and Alzheimer disease.

In our next expert Q&A we are delighted to welcome Prof. Bengt Winblad. Prof. Winblad is a prominent figure in geriatric medicine and Alzheimer's research, having served as Head of the Division of Neurogeriatrics at Karolinska Institutet and ...